XML 81 R64.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
Preferred Stock
Series Seed Preferred Stock [Member]
Preferred Stock
Series A Preferred Stock [Member]
Preferred Stock
Series A2 Convertible Preferred Stock [Member]
Preferred Stock
Series A3 Convertible Preferred Stock [Member]
Preferred Stock
Series CF Convertible Preferred Stock [Member]
Preferred Stock
Series B Preferred Stock [Member]
Preferred Stock
Series A Convertible Preferred Stock [Member]
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717   266      
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 0 $ 0 $ 27,482,061 $ (33,345,997) $ (5,857,645)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075)     6,291   6,291
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717)   1,611      
Issuance of common stock in public offering                 10,000,002   10,000,002
Issuance of common stock in public offering (in shares)               964      
Offering costs                 (2,116,957)   (2,116,957)
Exercise of over-allotment option, net of offering costs                 1,364,997   1,364,997
Exercise of over-allotment option, net of offering costs (in shares)               145      
Conversion of debt into common stock                 2,680,289   2,680,289
Conversion of debt into common stock (In shares)               454      
Conversion of related party notes and payables into common stock                 257,515   257,515
Conversion of related party notes and payables into common stock (in shares)               61      
Common stock issued in connection with business combination                 11,428,738   11,428,738
Common stock issued in connection with business combination (in shares)               1,318      
Exercise of warrants                 1,768,046   1,768,046
Exercise of warrants (in shares)               155      
Common stock issued pursuant to consulting agreement                 595,500   595,500
Common stock issued pursuant to consulting agreement (in shares)               97      
Issuance of common stock pursuant to equity line of credit                 367,696   367,696
Issuance of common stock pursuant to equity line of credit (in shares)               51      
Common stock and warrants issued in connection with notes                 501,658   501,658
Common stock and warrants issued in connection with notes (in shares)               52      
Stock-based compensation                 4,278,337   4,278,337
Stock-based compensation (Shares)               29      
Net loss                   (32,357,957) (32,357,957)
Ending balance at Dec. 31, 2021               $ 0 58,614,173 (65,703,954) (7,089,781)
Ending balance (in shares) at Dec. 31, 2021               521      
Stock-based compensation                 139,093   139,093
Net loss                   (7,832,942) (7,832,942)
Ending balance at Mar. 31, 2022               $ 0 59,954,848 (73,536,896) (13,582,048)
Ending balance (in shares) at Mar. 31, 2022               870      
Beginning balance (in shares) at Dec. 31, 2021               521      
Beginning balance at Dec. 31, 2021               $ 0 58,614,173 (65,703,954) (7,089,781)
Conversion of debt into common stock                     1,802,372
Net loss                     (17,366,866)
Ending balance at Jun. 30, 2022               $ 2 68,190,600 (83,070,820) (14,880,218)
Ending balance (in shares) at Jun. 30, 2022               16,470      
Beginning balance (in shares) at Dec. 31, 2021               521      
Beginning balance at Dec. 31, 2021               $ 0 58,614,173 (65,703,954) (7,089,781)
Issuance of common stock in public offering               $ 1 9,347,449   9,347,450
Issuance of common stock in public offering (in shares)               14,956      
Issuance of common stock and exercise of pre-funded warrants in public offering (in shares)               72,727      
Issuance of common stock and exercise of pre-funded warrants in public offering               $ 7 9,999,989   9,999,996
Offering costs                 (2,921,646)   (2,921,646)
Conversion of debt into common stock                     11,983,389
Common stock issued in connection with business combination                 1,000,000   1,000,000
Common stock issued in connection with business combination (in shares)               3,636      
Common stock issued pursuant to consulting agreement                 123,000   123,000
Common stock issued pursuant to consulting agreement (in shares)               30      
Stock-based compensation                 479,038   479,038
Net loss                   (38,043,362) (38,043,362)
Conversion of notes and derivative liability into common stock               $ 8 11,983,381   11,983,389
Conversion of notes and derivative liability into common stock (in shares)               79,807      
Warrant and common shares issued with notes                 1,368,741   1,368,741
Warrant and common shares issued with notes (in shares)               2,400      
Conversion of venture debt into Series A convertible preferred stock             $ 1   6,299,999   6,300,000
Conversion of venture debt into Series A convertible preferred stock (in shares)             6,300        
Ending balance at Dec. 31, 2022             $ 1 $ 18 96,294,123 (103,747,316) (7,453,174)
Ending balance (in shares) at Dec. 31, 2022             6,300 178,758      
Beginning balance (in shares) at Mar. 31, 2022               870      
Beginning balance at Mar. 31, 2022               $ 0 59,954,848 (73,536,896) (13,582,048)
Issuance of common stock in public offering               $ 1 9,347,449   9,347,450
Issuance of common stock in public offering (in shares)               14,956      
Offering costs                 (1,930,486)   (1,930,486)
Common stock and warrants issued in connection with notes                 98,241   98,241
Stock-based compensation                 119,759   119,759
Net loss                   (9,533,924) (9,533,924)
Conversion of notes and derivative liability into common stock                 600,790   600,790
Conversion of notes and derivative liability into common stock (in shares)               644      
Ending balance at Jun. 30, 2022               $ 2 68,190,600 (83,070,820) (14,880,218)
Ending balance (in shares) at Jun. 30, 2022               16,470      
Beginning balance (in shares) at Dec. 31, 2022             6,300 178,758      
Beginning balance at Dec. 31, 2022             $ 1 $ 18 96,294,123 (103,747,316) (7,453,174)
Offering costs                 (536,927)   (536,927)
Stock-based compensation                 105,594   105,594
Net loss                   (6,136,349) (6,136,349)
Ending balance at Mar. 31, 2023             $ 1 $ 23 102,020,620 (109,883,665) (7,863,022)
Ending balance (in shares) at Mar. 31, 2023             6,300 238,803      
Beginning balance (in shares) at Dec. 31, 2022             6,300 178,758      
Beginning balance at Dec. 31, 2022             $ 1 $ 18 96,294,123 (103,747,316) (7,453,174)
Net loss                     (1,092,088)
Ending balance at Jun. 30, 2023             $ 1 $ 31 109,263,332 (104,839,404) 4,423,960
Ending balance (in shares) at Jun. 30, 2023           1 6,300 316,906      
Beginning balance (in shares) at Mar. 31, 2023             6,300 238,803      
Beginning balance at Mar. 31, 2023             $ 1 $ 23 102,020,620 (109,883,665) (7,863,022)
Stock-based compensation                 101,500   101,500
Net loss                   5,044,260 5,044,260
Ending balance at Jun. 30, 2023             $ 1 $ 31 $ 109,263,332 $ (104,839,404) $ 4,423,960
Ending balance (in shares) at Jun. 30, 2023           1 6,300 316,906